QCG
EWTX icon

Quadrant Capital Group’s Edgewise Therapeutics EWTX Stock Holding History

Quadrant Capital Group’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-6
Closed -$189 – 1676
2026
Q1 		$189 Buy
+6
New +$173 ﹤0.01% 2671
2023
Q3 		– Sell
-41
Closed -$318 – 2711
2023
Q2 		$318 Buy
+41
New +$346 ﹤0.01% 2623
2022
Q4 		– Sell
-110
Closed -$1K – 2769
2022
Q3 		$1K Buy
+110
New +$1.11K ﹤0.01% 2505

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Quadrant Capital Group's EWTX Position: Q2 2026 in Review

Quadrant Capital Group sold out of Edgewise Therapeutics (EWTX) in Q2 2026, closing a stake of 6 shares — an estimated $189 sold.

Quadrant Capital Group first reported a position in EWTX in Q3 2022 and held it in 3 quarters. The position peaked at $1K in Q3 2022. 226 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Quadrant Capital Group reported no remaining Edgewise Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Quadrant Capital Group sold 6 Edgewise Therapeutics shares in Q2 2026, an estimated $189.
  • Quadrant Capital Group first reported a position in Edgewise Therapeutics in Q3 2022 and held it in 3 quarters.
  • Quadrant Capital Group's Edgewise Therapeutics position peaked at $1K in Q3 2022.
  • 226 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.